Corbus Pharmaceuticals Hldgs Inc CRBP

$6.13 -0.21 (-3.31%)

Valuation

Market cap
118,374,000
Revenue TTM
$0
Net income TTM
$-78,540,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
835,400
Avg volume
832,596
Day's range
$6.06 – $6.68
Shares out
18,671,000
Stochastic %K
4%
Beta
2.63
Analysts
Strong Sell
Price target
$35.89

Price

Company profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The...

Show more

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 963 0100
Website
https://www.corbuspharma.com
Address
500 River Ridge Drive, Norwood, United States

Latest news

Stocktwits

birdmine Oct 1, 6:49 PM
$CRBP sigh!!! TRASH!!!
1 replies
Pne01 Sep 30, 10:07 PM
$CRBP RA Capital filed 13-G and now second biggest owner with 9,9% after Cormorant.
0 replies
prismmarketview Sep 29, 7:49 PM
$CRBP First patient dosed in TEMPO-1, registrational trial of CRB-701 (Nectin-4-targeted ADC) in 2nd-line+ OPSCC (oropharyngeal squamous cell carcinoma). Randomized, ~250 patients, vs. investigator's choice of capecitabine/cetuximab/docetaxel. Primary endpoint: ORR (targets accelerated approval); OS: secondary, targets full approval conversion. Prior Phase 1/2 (3.6mg/kg, ASCO 2026): 42.9% confirmed ORR, 6.3-mo median response duration, 5.6-mo median PFS (ongoing analysis), patient count in that cohort not disclosed. ~14,000 US patients/year eligible for 2nd-line OPSCC treatment (market size, not a sales forecast). FDA Fast Track in HNSCC + cervical cancer, no approval yet. No results timeline given, watch enrollment pace and randomized readout. $CRBP #Biotech #Oncology https://prismmarketview.com/corbus-pharmaceuticals-doses-first-patient-in-registrational-crb-701-throat-cancer-trial/
0 replies
birdmine Sep 29, 1:32 PM
$CRBP this is such a trash company. Nothing but a money pit.
0 replies
shlomiko Sep 29, 1:29 PM
$CRBP
0 replies
ZekeBalderdash Sep 18, 4:45 PM
$CRBP Sooner or later (hopefully after ObesityWeek), analysts and the market will realize that CRB-913 has some potential to augment, compete with, or even displace GLP-1s. BP might pay a lot to own that potential and to keep it from the competition. The recent data removed the gravest doubts. With luck, the full dataset will confirm the pre-clinical research and increase the calculated odds of realizing each of those potential outcomes. In a truly rational market, those odds would largely determine the price. I'm sure it's higher than the company's cash holdings, where we now sit. The same logic applies to 701. And the combination of the two assets gives any potential buyers optionality - a Wall Street beloved.
1 replies
shlomiko Sep 18, 2:16 PM
$CRBP
0 replies
KayInDee Sep 18, 1:31 AM
$CRBP my friend told me that his friend was a CEO for 12 years and failed all the pipelines and asked me if I can hire him- he is smart. Should I hire him?
0 replies